---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006910"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:35:35.390033+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics Q3 net loss $5.1M; cash $6.4M; agenT-797 shows durable solid tumor benefit

## Summary
- Cash $6.4M at Sep 30, 2023, down from $19.6M at Dec 31, 2022; Q3 cash used in ops $4.2M.
- Q3 net loss $5.1M ($0.15/sh); 9-month net loss $17M ($0.50/sh), vs $20.2M ($0.60/sh) year ago.
- AgenT-797: >30% disease stabilization/biomarker response in heavily pretreated solid tumors; durable gastric cancer response.
- Randomized Phase 2 trial of agenT-797 in 2L gastric cancer to launch this year, externally funded, led by MSKCC.
- R&D expense down to $3.4M ($6.2M in Q3 2022) as company focuses iNKT platform and cGMP manufacturing.

## SEC filing metadata
- accession: 0001171843-23-006910
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/0001171843-23-006910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/f8k_110923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006910
- JSON: https://secwatch.observer/filing/0001171843-23-006910.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006910.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported third quarter 2023 results: net income $17 million, or $0.50 per share, EPS ($0.50).
  - Period: third quarter 2023
  - Net income: $17 million, or $0.50 per share
  - EPS: ($0.50)
  - Result: reported results
  source text: Net loss for the nine-months ended September 30, 2023 was $17 million, or $0.50 per share, compared to net loss for the same period in 2022 of $20.2 million or $0.60 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/0001171843-23-006910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.